Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts.
Matrix extracellular phosphoglycoprotein (MEPE) is an extracellular matrix protein that was first detected in tumor-induced osteomalacia (TIO). Investigations in mice revealed that MEPE is expressed in bone and teeth in a maturation-dependent manner, reaching its maximum during mineralization. However, from knockout experiments, although it has become clear that MEPE might function as a mineralization inhibitor, the exact mechanism of action is still unclear. Even less is known about the regulation of MEPE in men. Therefore, we have studied the time- and maturation-dependent expression of MEPE in two human osteoblast culture systems, the osteosarcoma cell line HOS 58 and primary trabecular osteoblasts. Cells were cultured for up to 29 days, and the influence of beta-glycerophosphate (bGP), ascorbate, transforming growth factor beta (TGF-beta), BMP-2, and dexamethasone was studied. HOS 58 cells showed no significant effect on MEPE gene expression up to 5.0 mM, but a significant inhibition was revealed at 10 and 20 mM, when osteocalcin (OC) expression was maximal. Under the same conditions, primary human osteoblasts showed no effect on MEPE gene expression. However, when cultured in the presence of 5 mM beta-glycerophosphate, ascorbate, and dexamethasone for 29 days, which are similar conditions to those described by Owen in his differentiation model in rat osteoblasts, a progressive inhibition of MEPE gene expression to 20% of the maximum was observed. Increasing osteocalcin expression indicated advancing differentiation. In conclusion, in contrast to the results in mice, when MEPE was maximally expressed during mineralization, in the human system, this factor seems to be maximally active in the proliferation and early matrix maturation phase. It was, however, strongly suppressed, associated with the mineralization phase.
Siggelkow
H
H
Department of Gastroenterology and Endocrinology, Georg-August-University, Göttingen, Germany. hsiggel@med.uni-goettingen.de
Schmidt
E
E
Hennies
B
B
Hüfner
M
M
D000328:Adult; D000368:Aged; D001205:Ascorbic Acid / Q000494:pharmacology; D001483:Base Sequence; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D017931:DNA Primers; D003907:Dexamethasone / Q000494:pharmacology; D015536:Down-Regulation; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D005994:Glycerophosphates / Q000494:pharmacology; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D008875:Middle Aged; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D010750:Phosphoproteins / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016212:Transforming Growth Factor beta / Q000494:pharmacology
C525718:BMP2 protein, human; C525719:Bmp2 protein, mouse; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D017931:DNA Primers; D016326:Extracellular Matrix Proteins; D005994:Glycerophosphates; D006023:Glycoproteins; C486579:MEPE protein, human; D010750:Phosphoproteins; D016212:Transforming Growth Factor beta; D003907:Dexamethasone; D001205:Ascorbic Acid; C031463:beta-glycerophosphoric acid